Abstract Details

Title A retrospective chart review to assess the efficacy and tolerability of switching from an alternative brand of IVIG to Panzyga® in patients with autoimmune neuromuscular disorders

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-032

Objective The purpose of this retrospective chart review was to assess the efficacy and tolerability of switching patients with autoimmune neuromuscular disorders, that were previously treated with another brand of IVIG, to Panzyga®, a novel IVIG.

Background IVIG is a blood product widely used for the treatment of autoimmune neuromuscular diseases. The province of Quebec in Canada procures IVIG through a public tender and defines hospital level quotas for the IVIG brands procured. In February 2017, Panzyga®, a novel IVIG developed by Octapharma, was allocated the largest proportion (40%), resulting in several patients with neuromuscular disorders transitioning their treatment to Panzyga®. Owing to its novelty, limited data exists on the tolerability of Panzyga® in patients with neuromuscular disorders.

Design/Methods A retrospective chart review was performed for patients who were previously treated with an alternative brand of IVIG before switching to Panzyga®. Tolerability and ongoing efficacy of Panzyga® compared to other IVIG brands were assessed pre- and post-switch using the motor component of the Neuropathy Impairment Score (NIS-motor) and the Clinical Global Impression Scale-Improvement (CGI-I). Pre- and post-switch adverse events (AEs) were recorded.

Results Fourteen patients (eleven males) were included in the chart review. Diagnoses included chronic idiopathic demyelinating polyneuropathy (9 patients), multifocal motor neuropathy (1) and myasthenia gravis (4). There was no difference in pre- and post-switch mean NIS-motor scores. For the majority of patients, symptoms remained unchanged after switching brands as measured by the CGI-I. Most patients on IVIG did not experience AEs; for those who did, most were mild both pre- and post-switch. The most frequently reported AE was headache.

Conclusions Preliminary results suggest that the safety, tolerability and ongoing efficacy of Panzyga® in neuromuscular patients is similar to existing IVIG brands as observed in routine clinical practice. Future studies may wish to validate these findings with a larger cohort of patients.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Rami Massie, MD (McGill University)	Dr. Massie has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Gowlingwlg. Dr. Massie has received personal compensation in the range of $500-$4,999 for serving as a Lecturer with Pfizer. Dr. Massie has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Argenx.

��ɫ��

��ɫ��